Health Catalyst, Inc.

Health Catalyst, Inc. Q2 FY2019 earnings

HCAT

Quarter ended Jun 2019.

Q3 FY2019 →
Revenue
$36.8M
Operating margin
-25.4%
Net income
-$10.7M

Summary

Health Catalyst reported second quarter revenue of $36.8 million, up 60% from $23.0 million in the same quarter a year earlier. Revenue for the six months ended June 30, 2019 was $72.0 million, up 65% from $43.6 million. Not all of that was organic. Medicity, acquired on June 29, 2018, contributed $6.4 million in the quarter. Organic growth was $7.4 million, or 32%. Technology revenue rose 87% and professional services revenue rose 36%. Technology was 55% of total revenue in the quarter, against 47% a year earlier, because Medicity revenue is mostly technology. The company expects year over year revenue growth rates to slow in the second half of 2019 compared with the first half.

Profitability improved but stayed deeply negative. Loss from operations was $9.4 million, narrower than the $18.8 million loss a year earlier. Net loss was $10.7 million, narrower than $19.3 million. Operating margin was negative 25.4%, up from negative 81.8%. The prior year quarter carried $8.3 million of tender offer payments deemed compensation expense, so part of the swing is a comparison effect rather than an operating change. Diluted loss per share was $21.98, worse than $3.53, because $98.6 million of accretion on redeemable convertible preferred stock is deducted before reaching the loss attributable to common stockholders. That accretion ends now that the preferred stock converted to common stock at the IPO.

Non-GAAP figures track the same direction. Total Adjusted Gross Profit was $19.3 million, up from $10.9 million, and Total Adjusted Gross Margin was 52%, up from 47%. Adjusted EBITDA was negative $5.7 million, better than negative $8.0 million. Inside gross margin the two segments split. Adjusted Technology Gross Margin fell to 65% from 70% on costs from moving customers to third party hosted data centers with Microsoft Azure. Adjusted Professional Services Gross Margin rose to 37% from 28%, helped by higher services revenue, better utilization, and slower than anticipated hiring during the quarter. Management expects the Azure migration to keep pressuring technology gross margin in the near term.

Cash use is easing. Net cash used in operating activities was $13.6 million for the six months ended June 30, 2019, against $21.4 million a year earlier. Purchases of property and equipment were $1.1 million, up from $0.5 million. Deferred revenue stood at $41.7 million at June 30, 2019, and remaining performance obligations at $63.9 million. Cash, cash equivalents, and short-term investments were $54.1 million at June 30, 2019. The IPO closed on July 29, 2019, after the quarter ended, with 8,050,000 shares sold at $26.00 each, net proceeds of $194.6 million, and estimated offering costs of $4.4 million. Pro forma for the offering, cash, cash equivalents, and short-term investments reach $248.7 million.

Guidance points to a wider loss next quarter. For the third quarter of 2019, management guides on total revenue and expects an Adjusted EBITDA loss between $11.2 million and $9.2 million. For full year 2019, management guides on total revenue and expects an Adjusted EBITDA loss between $31.7 million and $29.7 million. The company does not reconcile the Adjusted EBITDA outlook to net loss.

Risks are the usual ones for a newly public healthcare analytics vendor. Medicity customers have historically produced a lower dollar based retention rate, and management expects flat to declining revenue from them. Sales and marketing, research and development, and general and administrative expenses are all expected to grow in absolute dollars, with added public company costs in general and administrative. The company also cites changes in laws and regulations, the results of litigation or a security incident, the loss of key customers or partners, and the difficulty of recruiting and retaining qualified team members. Federal and state net operating loss carryforwards could be limited by ownership changes under Sections 382 and 383.

Forecast

Management guidance
ReportedGuidance

Guided revenue, Q3 FY2019$36.8M – $38.8M
Midpoint$37.8M
Growth vs Q2 FY2019+2.7%
Q3 2019
Adjusted EBITDA$(11.2) million - $(9.2) million
Full Year 2019
Total revenue$149.8 million - $151.8 million
Adjusted EBITDA$(31.7) million - $(29.7) million
second half of 2019
Year-over-year revenue growth ratesslow

Reported figures

GAAP, from SEC filings
MetricQ2 FY2019Q1 FY2019QoQQ2 FY2018YoY
Revenue$36.8M————
Research & development$9.7M————
Sales & marketing$10.4M————
General & administrative$6.1M————
Total operating expenses$28.5M————
Operating income (loss)-$9.4M————
Operating margin-25.4%————
Net income (loss)-$10.7M————
Net margin-29.1%————

Risks

HIGHCloud Migration

The migration of customers from on-premise and company-managed data centers to Microsoft Azure is more costly per customer, and Adjusted Technology Gross Margin decreased from 70% for the three months ended June 30, 2018 to 65% for the three months ended June 30, 2019. Management expects the transition to continue to pressure Adjusted Technology Gross Margin in the near term, with planned transitions substantially complete by the end of 2020.

HIGHAcquisition Integration

Medicity customers have historically generated a lower Dollar-based Retention Rate than DOS Subscription Customers, and management expects flat to declining revenue from Medicity customers in the foreseeable future. Because the Medicity acquisition closed on June 29, 2018, management expects year-over-year revenue growth rates to slow during the second half of 2019 compared with the first half of 2019.

HIGHCompetition

The healthcare analytics market is intensely competitive, including against EHR vendors such as Epic Systems and Cerner and larger competitors such as Optum Analytics and IBM with greater resources and established relationships. Increased competition is likely to result in pricing pressures that could negatively impact sales, profitability, or market share.

HIGHRenewal Risk

The company derives a significant portion of revenue from renewing existing customer contracts, but most subscription contracts are terminable after one year upon 90 days' notice and certain contracts are terminable for convenience after a specified period. Customers may also renew at lower fee levels or decline additional purchases, which could reduce future revenue or constrain growth.

HIGHDebt Covenants

The OrbiMed Credit Facility is secured by a lien on substantially all assets, including intellectual property, and contains affirmative and negative covenants restricting asset transfers, additional indebtedness, mergers, dividends, and liens. A default could let the lender declare all obligations immediately due and payable and take control of pledged assets.

MEDIUMData Access

The Solution depends on sourcing data from third-party clinical, financial, and operational systems, and vendors may engage in information blocking that inhibits access. The March 3, 2019 Proposed Rule under the 21st Century Cures Act may not be finalized for some time and may be modified or ignored in the interim, which could limit data access and make enforcement costly.

MEDIUMSales Cycle

New customer sales cycles are long and unpredictable, averaging 11 months from prospect qualification to first sale and in some cases exceeding 24 months. Management also notes customers are large, complex organizations with long procurement cycles that may lead to declines in the pace of new customer additions.

MEDIUMTalent Retention

The company depends on senior management and key employees, and several senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints. Co-founder Steven Barlow was called to serve full-time from June 2017 to June 2020, with his leave likely extending until August 2020, removing a senior leader from professional services.

MEDIUMNet Losses

The company had net losses of USD 24.4 million for the six months ended June 30, 2019 and USD 62.0 million for the year ended December 31, 2018, and an accumulated deficit of USD 557.2 million as of June 30, 2019. It expects costs to increase and may need additional equity or debt financing to fund operations.

MEDIUMPricing

In the fourth quarter of 2018, the company began introducing new pricing for its Solution to new customers, with full effect expected in future years. Its assessments may be inaccurate, leading to underpricing or overpricing and potential continued adjustments to the pricing model.

MEDIUMRevenue Mix

Technology and professional services offerings have materially different gross margin profiles, and for the six months ended June 30, 2019 technology revenue and professional services revenue represented 56% and 44% of total revenue, respectively. Changes in mix can impact future Total Adjusted Gross Margin.

MEDIUMRegulatory

The company must obtain certification from governmental agencies such as AHRQ to sell certain analytics applications and services in the United States, and cannot be certain that its Solution will continue to meet these standards. Failure to comply could result in loss of certification, restrict offerings, and cause customer loss.

MEDIUMClinical Liability

If analytics applications, content, or services are associated with faulty clinical decisions or treatment, or if data analyses are incomplete or inaccurate, customers, clinicians, or patients could assert product liability or medical malpractice claims. Contractual limitations and insurance may not be enforceable or sufficient.

Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q2 FY2019 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.